![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Bentham Science Publishers
E-ISSN: 2212-3873|18|3|235-240
ISSN: 1871-5303
Source: Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol.18, Iss.3, 2018-04, pp. : 235-240
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Valsartan improves quality of life for patients with heart failure
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 363, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Valsartan improves quality of life for patients with heart failure
Inpharma, Vol. 1, Iss. 1339, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)